In the case of malignant intestinal obstruction, surgery often carries important mortality and morbidity risks, and feasibility is neither realistic nor reasonable. A total of 4 clinical cases of intestinal obstruction caused by advanced gastrointestinal cancers in their terminal phase are described. The association of analgesics, corticosteroids, antiemetics, and octreotide was effective to relieve symptoms of intestinal obstruction for the remaining lifetime. The insertion of a nasogastric tube was avoided in 3 of 4 cases. Death occurred 51, 56, and 64 days after clinical and radiological diagnosis of irreversible intestinal obstruction. This combination of drugs appears very powerful and well tolerated. The relatively long survival that ...
Octreotide, a somatostatin analogue, has been shown to inhibit the growth of gastrointestinal cancer...
Bowel obstruction may be an inoperable complication in patients with end-stage cancer. Scopolamine b...
Bowel obstruction is the most common complication in patients with ovarian cancer. Management of thi...
Gastrointestinal obstruction is a common problem in advanced malignant disease, but its management r...
Octreotide in the management of intestinal obstruction in terminal cancer patients
The use of symptomatic agents has greatly improved the medical treatment of advanced cancer patient...
Malignant bowel obstruction and intractable diarrhea in advanced cancer are common devastating syndr...
With an increase in the number of patients with malignant tumors, managing various symptoms of termi...
Intestinal obstruction is a common complication in patients with advanced abdominal or pelvic cancer...
Early and intensive pharmacological treatment not only may reduce gastrointestinal symptoms but also...
Intestinal obstruction is a common and distressing clinical complication in ovarian cancer. The aim ...
Objective: In patients with advanced cancer, malignant bowel obstruction (MBO) causes gastrointestin...
In advanced cancer patients with inoperable bowel obstruction, the administration of antisecretive a...
Inoperable malignant intestinal obstruction (IMIO) is a severe complication in patients with cancer,...
Patients with incurable, advanced abdominal or pelvic malignancy often present to acute surgical dep...
Octreotide, a somatostatin analogue, has been shown to inhibit the growth of gastrointestinal cancer...
Bowel obstruction may be an inoperable complication in patients with end-stage cancer. Scopolamine b...
Bowel obstruction is the most common complication in patients with ovarian cancer. Management of thi...
Gastrointestinal obstruction is a common problem in advanced malignant disease, but its management r...
Octreotide in the management of intestinal obstruction in terminal cancer patients
The use of symptomatic agents has greatly improved the medical treatment of advanced cancer patient...
Malignant bowel obstruction and intractable diarrhea in advanced cancer are common devastating syndr...
With an increase in the number of patients with malignant tumors, managing various symptoms of termi...
Intestinal obstruction is a common complication in patients with advanced abdominal or pelvic cancer...
Early and intensive pharmacological treatment not only may reduce gastrointestinal symptoms but also...
Intestinal obstruction is a common and distressing clinical complication in ovarian cancer. The aim ...
Objective: In patients with advanced cancer, malignant bowel obstruction (MBO) causes gastrointestin...
In advanced cancer patients with inoperable bowel obstruction, the administration of antisecretive a...
Inoperable malignant intestinal obstruction (IMIO) is a severe complication in patients with cancer,...
Patients with incurable, advanced abdominal or pelvic malignancy often present to acute surgical dep...
Octreotide, a somatostatin analogue, has been shown to inhibit the growth of gastrointestinal cancer...
Bowel obstruction may be an inoperable complication in patients with end-stage cancer. Scopolamine b...
Bowel obstruction is the most common complication in patients with ovarian cancer. Management of thi...